Fate Therapeutics develops off-the-shelf cell immunotherapies made from stem cells, mainly for autoimmune diseases and cancer. FATE reports earnings on Thu, Nov 12, 2026. Analyst consensus is Buy, based on the latest ratings from 3 firms (2 buy, 1 hold, 0 sell).
Prices, price targets and earnings estimates for FATE are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in FATE in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether FATE is in one of them and how their past FATE trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Fate Therapeutics
Fate Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California. It develops off-the-shelf cellular immunotherapies, mainly CAR T-cell and natural killer cell product candidates made from induced pluripotent stem cells. Its current focus is on treating autoimmune diseases such as lupus, along with cancer, and its candidates are being studied in clinical trials for patients with these conditions.
